Cellid Co. Ltd (299660) - Net Assets
Based on the latest financial reports, Cellid Co. Ltd (299660) has net assets worth ₩74.21 Billion KRW (≈ $50.29 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩110.87 Billion ≈ $75.13 Million USD) and total liabilities (₩36.66 Billion ≈ $24.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Cellid Co. Ltd for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩74.21 Billion |
| % of Total Assets | 66.93% |
| Annual Growth Rate | 54.43% |
| 5-Year Change | 91.45% |
| 10-Year Change | N/A |
| Growth Volatility | 110.3 |
Cellid Co. Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Cellid Co. Ltd's net assets have evolved over time, based on quarterly financial data. Check 299660 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Cellid Co. Ltd (2015–2025)
The table below shows the annual net assets of Cellid Co. Ltd from 2015 to 2025. For live valuation and market cap data, see market cap of Cellid Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩74.21 Billion ≈ $50.29 Million |
+44.93% |
| 2024-12-31 | ₩51.20 Billion ≈ $34.70 Million |
+26.44% |
| 2023-12-31 | ₩40.50 Billion ≈ $27.44 Million |
+80.47% |
| 2022-12-31 | ₩22.44 Billion ≈ $15.21 Million |
-42.11% |
| 2021-12-31 | ₩38.76 Billion ≈ $26.27 Million |
-18.05% |
| 2020-12-31 | ₩47.30 Billion ≈ $32.05 Million |
-7.86% |
| 2019-12-31 | ₩51.33 Billion ≈ $34.79 Million |
+280.35% |
| 2018-12-31 | ₩13.50 Billion ≈ $9.15 Million |
+344.15% |
| 2017-12-31 | ₩-5.53 Billion ≈ $-3.75 Million |
-2585.53% |
| 2016-12-31 | ₩-205.83 Million ≈ $-139.49K |
-121.41% |
| 2015-12-31 | ₩961.38 Million ≈ $651.51K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cellid Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7554864192000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩151.28 Billion | 203.86% |
| Total Equity | ₩74.21 Billion | 100.00% |
Cellid Co. Ltd Competitors by Market Cap
The table below lists competitors of Cellid Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
$34.55 Million |
|
Unite Group PLC
LSE:UTG
|
$34.55 Million |
|
Hudson Global Inc
NASDAQ:HSON
|
$34.56 Million |
|
Corem Property Group AB (publ)
ST:CORE-A
|
$34.56 Million |
|
Tourindo Guide Indonesia Pt
JK:PGJO
|
$34.51 Million |
|
Radana Bhaskara Finance Tbk
JK:HDFA
|
$34.50 Million |
|
EYG Gayrimenkul Yatirim Ortakligi A.S.
IS:EYGYO
|
$34.49 Million |
|
Monalisa
KO:012690
|
$34.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellid Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 51,203,097,970 to 74,206,585,600, a change of 23,003,487,630 (44.9%).
- Net loss of 12,069,197,070 reduced equity.
- New share issuances of 35,018,385,910 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.07 Billion | -16.26% |
| Share Issuances | ₩35.02 Billion | +47.19% |
| Other Changes | ₩54.30 Million | +0.07% |
| Total Change | ₩- | 44.93% |
Book Value vs Market Value Analysis
This analysis compares Cellid Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.69x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩-30.76 | ₩1727.00 | x |
| 2017-12-31 | ₩-762.50 | ₩1727.00 | x |
| 2018-12-31 | ₩1643.61 | ₩1727.00 | x |
| 2019-12-31 | ₩5358.73 | ₩1727.00 | x |
| 2020-12-31 | ₩4876.51 | ₩1727.00 | x |
| 2021-12-31 | ₩3479.32 | ₩1727.00 | x |
| 2022-12-31 | ₩2014.21 | ₩1727.00 | x |
| 2023-12-31 | ₩2644.08 | ₩1727.00 | x |
| 2024-12-31 | ₩2155.06 | ₩1727.00 | x |
| 2025-12-31 | ₩2515.22 | ₩1727.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellid Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -136.50%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.49x
- Recent ROE (-16.26%) is above the historical average (-38.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -117.02% | -175.83% | 0.23x | 2.95x | ₩-1.22 Billion |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-1.75 Billion |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-4.86 Billion |
| 2018 | -83.63% | 0.00% | 0.00x | 1.05x | ₩-12.64 Billion |
| 2019 | -4.86% | 0.00% | 0.00x | 1.02x | ₩-7.63 Billion |
| 2020 | -8.72% | 0.00% | 0.00x | 1.04x | ₩-8.86 Billion |
| 2021 | -33.72% | -1437.76% | 0.02x | 1.50x | ₩-16.95 Billion |
| 2022 | -101.90% | -4763.45% | 0.01x | 2.04x | ₩-25.11 Billion |
| 2023 | -28.67% | 0.00% | 0.00x | 1.58x | ₩-15.66 Billion |
| 2024 | -23.94% | -294.33% | 0.05x | 1.49x | ₩-17.38 Billion |
| 2025 | -16.26% | -136.50% | 0.08x | 1.49x | ₩-19.49 Billion |
Industry Comparison
This section compares Cellid Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $256,967,939,787
- Average return on equity (ROE) among peers: -5.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellid Co. Ltd (299660) | ₩74.21 Billion | -117.02% | 0.49x | $34.53 Million |
| ORIENTBIO Inc. (002630) | $60.51 Billion | 0.00% | 1.04x | $69.59 Million |
| Green Cross (005250) | $350.47 Billion | 6.04% | 6.94x | $285.94 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $2.32 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $418.84 Million |
| GeneOne Life Science Inc (011000) | $36.54 Billion | -64.94% | 0.25x | $164.07 Million |
| HLB Co. Ltd (028300) | $15.50 Billion | 0.00% | 1.33x | $2.78 Billion |
| Mgenplus Co. Ltd. (032790) | $17.78 Billion | 0.00% | 1.54x | $16.18 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $15.25 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.71 Billion | 14.88% | 0.35x | $24.62 Million |
| Hyundai Bioscience Co. Ltd (048410) | $51.22 Billion | -16.80% | 0.80x | $403.52 Million |
About Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more